Key Highlights

  • RSI at 54.46 and Commodity Channel index at 68.09 are the lowest of the eight, both well short of extended territory.
  • The only name in the group with a Buy rather than Strong buy Moving Average rating.
  • The only name negative over one week, at -1.18 per cent, while up 6.37 per cent over one year.

Technical position

RSI 14 reads 54.46, the lowest of the eight names carrying a positive trend structure, with the Commodity Channel Index at 68.09, also the lowest and well below the 100 line. The stochastic sits at 60.19 on %K against 60.82 on %D, leaving more room above than any other name in the group. Momentum over ten periods at 0.14 and the Awesome Oscillator at 0.30 are the softest paired readings here. The technical rating is Buy, the moving average rating Buy and the oscillator rating Neutral. The 21-period exponential moving average holds above the 50-period average, so the trend structure is aligned without being extended.

Fundamental snapshot

Lexeo Therapeutics sits in health technology with a Market Capitalisation of USD 411.05 million. The shares last traded at USD 5.01, down 2.34 per cent on the session. Trailing Diluted Earnings per Share is negative at USD 1.16, so no price to earnings ratio applies, with earnings per share growth of 64.51 per cent. No Dividend is paid. Analyst consensus reads Strong buy.

Price performance

The stock is down 1.18 per cent over one week, the only name in its peer group negative on that window, while up 6.60 per cent over one month and 6.37 per cent over one year. It is down 1.38 per cent over three months, 26.65 per cent over six months, 49.65 per cent year to date and 47.26 per cent on an all time basis. One month Volatility reads 6.19 per cent.

This article is general information only and does not take into account any individual objectives, financial situation or needs. It is not a recommendation to buy, sell or hold any security. All details are as stated in the company announcement or third party research referenced and are subject to change. Past performance is not a reliable indicator of future performance. Investors should consider the appropriateness of any information having regard to their own circumstances and seek independent financial advice before making any financial decision.